Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
August 20, 2014, 03:19:04 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 635229
  • Total Topics: 48184
  • Online Today: 243
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 3
Guests: 126
Total: 129

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Prostratin - A Potential Cure Strategy  (Read 2429 times)

0 Members and 1 Guest are viewing this topic.

Offline chico_mkd

  • Member
  • Posts: 21
Prostratin - A Potential Cure Strategy
« on: April 06, 2012, 04:01:49 PM »
Have anybody read something about this?


http://aidsresearch.org/cure-research/prostratin/

Offline ichigo_kun

  • Member
  • Posts: 49
Re: Prostratin - A Potential Cure Strategy
« Reply #1 on: April 06, 2012, 04:30:54 PM »
yeah, theyre still on the process of approval for phase 1 human trial. this sounds interesting... lots of good news about trials and research this year. ;)

Our Progress


Table 1: Prostratin progress report. The required experiments for IND submission are listed, as well as their completion status.  All of these experiments must be completed and meet FDA standards before prostratin can be approved for in-human clinical trials.
Our Progress in Developing Prostratin

Significant progress has been made in the study of prostratin and its possible role as a novel anti-HIV therapeuticówork conducted by AIDS Research Alliance, as well as other laboratories.  Our goal is to develop prostratin as an anti-HIV treatment that targets the viral reservoirs, and thus eradicate HIV from infected individuals.

AIDS Research Alliance has completed both in vitro and in vivo studies to examine the efficacy of prostratin to activate the HIV latent reservoir, as well as to identify potential toxicity, genotoxicity and pharmacokinetic limitations.  In vitro studies examining the efficacy of prostratin were performed using both cell line models and patient samples.  After six hours of treatment with prostratin in two latently infected cell lines, prostratin was able to stimulate HIV activity, as measured by reverse transcriptase activity. 

CD4+ T cells were isolated from HIV+ patients on HAART and treated with prostratin.  Results confirmed the ability of prostratin to stimulate HIV expression in resting T cells.  In vivo pharmacology studies have also been performed to determine the single-dose range and the maximum tolerated dose.  The pharmacokinetics of prostratin were determined following intravenous and oral administration.  Gender differences in the distribution and metabolism of prostratin were examined, and no unique differences were observed.  Genotoxicity assays were performed, and results indicate that prostratin did not induce significant genotoxicities.

The results of these studies were submitted to, and reviewed by, the U.S. Food & Drug Administration [FDA] pursuant to a pre-Investigational New Drug [pre-IND] consultation requested by AIDS Research Alliance.  In response, the FDA recommended additional experiments to complete prior to IND submission.  These studies include determining the effects of combining prostratin with existing anti-HIV drugs to determine if resistant virus will emerge from treatment with prostratin.  Other studies will seek to determine if activation by prostratin is reversible, and whether there are any effects following administration of the drug.  In addition, a series of IND-enabling pharmacology and toxicology studies of prostratin have been designed to examine toxicity and toxicokinetics following IV-infusion of prostratin.

These remaining studies must be completed before AIDS Research Alliance can submit the IND [Investigational New Drug] application to the FDA.  Upon approval of prostratin as an IND, a Phase I human clinical trial will be conducted to evaluate the safety and pharmacokinetics of prostratin given via intravenous administration to HIV-infected individuals on antiretroviral therapy. 

Offline nursepoz24

  • Member
  • Posts: 28
Re: Prostratin - A Potential Cure Strategy
« Reply #2 on: April 06, 2012, 10:32:20 PM »
let us hope that this reasearch works. God Bless to all the POZ.

Offline geobee

  • Member
  • Posts: 274
Re: Prostratin - A Potential Cure Strategy
« Reply #3 on: April 07, 2012, 07:00:03 PM »
The ability to synthetically produce protratin will, hopefully, advance it further.  It was made from the bark of a rare tree (in Sonoma, I think?) and it was expensive and difficult to obtain for tests / trials.

Offline elf

  • Member
  • Posts: 601
Re: Prostratin - A Potential Cure Strategy
« Reply #4 on: April 07, 2012, 07:25:47 PM »
This has already been discussed, a few years ago, since the name prostratin sounds familiar to me.  :)
Let's have a Kiki!

Offline AlexMerida

  • Member
  • Posts: 28
Re: Prostratin - A Potential Cure Strategy
« Reply #5 on: April 07, 2012, 09:26:58 PM »
I recomed the use of the word "potential"  to my students when they realy do not know if their aproach was succesful.

Potentential catchs the atention of people...

You can put  like ....this has the "potential" to resolve that

And it is allowed even without any lab results  (proof of concept)

If you have a good imagination you can get many propolsal aproved with tha beautiful word...potential

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.